A Phase 1 Placebo-Controlled Double-Blind First-In-Human Single Ascending Dose Study to Assess the Safety Pharmacokinetics and Pharmacodynamics of Intravenously-Administered SelK2 in Healthy Subjects and Patients with a Diagnosis of Crohn's Disease.
-
- STATUS
- Not Recruiting
Updated on 19 February 2024
Summary
The purpose of this study is to evaluate the safety and tolerability of a single dose of the study drug, SELK2, at increasing dose levels.
Description
The purpose of this study is to evaluate the safety and tolerability of a single dose of the study drug, SELK2, at increasing dose levels.
Details
| Condition | Crohn's disease |
|---|---|
| Age | 100years or below |
| Clinical Study Identifier | TX5888 |
| Last Modified on | 19 February 2024 |
How understandable was the trial content above?
Hard to understand
Easy to understand
Similar trials to consider
Loading...
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteerStudy Definition
WikipediaAdd a private note
- Select a piece of text.
- Add notes visible only to you.
- Send it to people through a passcode protected link.